HCPCS Level II code A9513 designates Lutetium Lu 177 dotatate supplied for therapeutic use and billed per 1 millicurie. This radiopharmaceutical is used in targeted peptide receptor radionuclide therapy for select neuroendocrine tumors and represents an important component of advanced oncologic outpatient treatment. Nationally, the code matters because it captures the supply unit for a high-cost, specialty radiopharmaceutical that has implications for facility billing, drug acquisition costs, and payer coverage policies.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, expected site-of-service patterns, and what to expect in payer engagement for this item. The publication provides benchmarks and policy-relevant context where available, including common billing practices for radiopharmaceutical units, coding considerations tied to single-unit reporting, and how payers typically categorize such therapies for coverage and payment. Data not available in the input will be noted as such; the content focuses on national-level implications, clinical rationale for the supply, and practical billing context for hospital outpatient and infusion settings.